Life Sciences

Whether your team of researchers and innovators is developing a new drug or medical device, seeking FDA approval, devising an exit strategy, going public or staying private, Weaver’s diverse team of professionals possesses deep knowledge of the intellectual property landscape, regulatory requirements, reimbursement strategies and commercial aspects. With a profound depth and breadth of experience in the life sciences industry, our professionals can guide you carefully and confidently through any phase of your development process.

Connect with us

Featured

Trending
Insights & Resources

Article

Biopharma Growth Reflects a Resilient 2024

J.P. Morgan’s Q3 2024 Biopharma Report highlights robust venture investments, shifting licensing trends and a resurgence in IPO activity.

Article

KPMG 2024’s Biopharma Strategy Outlook Report

KPMG has released their 2024 biopharma report detailing the challenges and opportunities for pharma companies moving forward into the new year.

Article

Q2 In Review: J.P. Morgan’s US Medtech Licensing and Venture Report

The medical technology, or medtech, industry is poised for a transformative year despite soft IPO activity the first half of 2024. Learn more here.

Article

Q2 In Review: J.P. Morgan’s U.S. Biopharma Licensing and Venture Report

The biopharma industry has experienced a resurgence the first part of 2024. J.P. Morgan’s Q2 report shares critical insights into the future of the industry.

Article

The Road to Regulatory Approval: Understanding FDA Special Review Designations

Unravel life sciences industry complexities, and discover the differences between FDA special review designations like Fast Track, Priority Review and Breakthrough.

Article

New York City Reinstates the Biotech Tax Credit

The credit is aimed at bolstering and incentivizing the emerging biotechnology sector to create jobs and invest in NYC and is available 1/1/23-1/1/26.

Explore all insights

Assisting you to go public.

Weaver offers integrated services that help you with compliance standards for developing new drugs and devices, going public and establishing IPOs, selling your company and investor relations. Our team knows how to plan your exit strategy and how to structure your taxes — no matter what you decide.

Once you’re public, our professionals can help you with comprehensive tax, audit advisory services for public companies. Our experience gives us the ability to ask the right questions and to help you with some of the most important transitions you’ll face.

Helping you to stay private.

Our professionals know the tax structures and exit strategies for staying private, too. Weaver’s team offers valuations, equity instruments, audit preparation and a host of services covering regulatory standards and business process improvements for the life sciences industry. We’ll help you stabilize and be prepared for new opportunities as they come.

Featured

CPRIT Grant Compliance Services

When you are awarded a grant from the Cancer Prevention and Research Institute of Texas (CPRIT) to fund new research or product development, doors open to innovation, growth and prestige. Along with these opportunities, you also incur responsibilities to manage and report grant funds in compliance with complex CPRIT requirements. Whether or not you have in-house staff with grant management experience the annual single audits or agreed-upon procedures can present a challenge. Our team can help.

Learn More

Meet the team